Levotan

Quick links to important sections

Levotan

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levotan

Property Description
Active ingredient Levocetirizine, Ambroxol
Form Tablets, Syrup, Capsule (Oral)
Pharmacological class Antihistamine, Mucolytic Agent
Origin Synthetic (Fixed Dose Combination)
General purpose Relief of allergic and muco-obstructive symptoms

Levotan: Defining the Combination Respiratory Medication

Levotan is a specialized combination respiratory medication defined by its identity as a fixed dose combination (FDC) of two distinct therapeutic agents. This formulation is clinically recognized for its synergistic approach, merging a potent antihistamine with an effective mucolytic agent to provide integrated support. The FDC structure is a strategic development that ensures the simultaneous and consistent application of both components, simplifying management for individuals who experience both allergic and secretion-related symptoms concurrently.

This entity is a synthetic pharmaceutical preparation, delivered via the oral route of administration, and is commonly supplied as Tablets, Syrup, or Capsules.

Active Ingredients and Composition of Levotan

Levotan is composed of the active ingredients: Levocetirizine and Ambroxol. Levocetirizine is the anti-allergic component, a selective second-generation antihistamine that operates as a histamine H1-receptor antagonist. Ambroxol, conversely, is the mucoactive drug, classified as a secretolytic agent and expectorant. This indicates that the medicine has properties for thinning mucus and supporting airway clearance.

What is the General Purpose of Levotan’s Dual Action?

The general purpose of Levotan’s formulation is to deliver dual action for integrated relief of discomfort. The antihistamine action mitigates the inflammatory response, reducing allergic irritation, which is key in managing symptoms like nasal congestion or postnasal drip associated with allergies. Concurrently, the secretolytic therapy works to liquefy viscous mucus and enhances its transport, facilitating its expulsion from the respiratory tract. This combined approach is effective in supporting the respiratory tract by simultaneously addressing both allergic and secretion-related burdens, leading to an overall reduction in the severity of a persistent productive cough.

What side effects are possible with Levotan?

Possible Side Effects and Safety Information

The safety profile of this fixed-dose combination, incorporating Levocetirizine and Ambroxol, is officially documented based on regulatory classifications and post-marketing surveillance for its active components. The adverse reactions are categorized by frequency and the body system affected, aligning with standard regulatory frameworks.

Common and Expected Regulatory Observations

Adverse reactions classified as Common in official labeling typically affect the central nervous and gastrointestinal systems. These include somnolence (drowsiness), headache, fatigue, dry mouth, and nausea. Other common observations include pharyngitis and changes in taste perception, known as dysgeusia.

Serious Adverse Reactions

Regulatory documents also detail rare but clinically serious adverse reactions, which are often reported through post-marketing experience. These include severe systemic reactions such as anaphylaxis and angioedema. Furthermore, the mucolytic component has been associated with the documented risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome.

Safety Constraints and Special Populations

Official safety information explicitly defines constraints for specific populations. Use of the Levocetirizine component is contraindicated in end-stage renal disease (creatinine clearance less than 10 mL/min) due to reduced clearance. Caution is also advised regarding use in patients with severe hepatic impairment. A documented safety note exists regarding the use of the medicine with alcohol or other Central Nervous System (CNS) depressants, which may lead to additional impairment of alertness. Additionally, the label notes that pruritus (itching) has been reported following the discontinuation of long-term Levocetirizine use.

Overdose and Emergency Response

Overdose and when to seek help must strictly follow official regulatory guidance. Suspected or confirmed ingestion exceeding the prescribed maximum dosage requires immediate medical attention. Contact a Poison Control center or emergency services without delay, as the potential for profound CNS depression is a documented risk.

Documented clinical manifestations of overdose are typically dual. The first set involves Central Nervous System (CNS) effects, which can present as somnolence, drowsiness, or stupor in adults. The second set includes Gastrointestinal (GI) symptoms, such as nausea, vomiting, diarrhea, or heartburn, which are extensions of known adverse effects.

There is no known specific antidote for Levotan overdose, meaning treatment is strictly symptomatic and supportive. Regulatory documents state that procedures like gastric lavage or the use of activated charcoal may be considered in specific cases by medical professionals. Dialysis or forced diuresis are documented as ineffective for removal of the antihistamine component.

A specific regulatory note applies to pediatric patients, where the overdose presentation may initially involve agitation or restlessness before the onset of profound drowsiness. Patients with existing renal impairment may face a potentially greater risk during an overdose event, requiring careful clinical monitoring and possible hospital observation.

Therapeutic Uses of Levotan

What Levotan Treats: Main Uses and Benefits

Levotan is commonly used to provide supportive symptomatic relief in conditions marked by a combination of symptoms related to allergic irritation and symptoms that create noticeable physiological strain due to secretions. This combination approach is relevant in contexts where additional symptomatic management is appropriate for both inflammatory or irritative states and secretion clearance simultaneously. The medication is utilized for such dual-symptom management.

The medication is applied across domains involving acute or recurrent episodes characterized by heightened symptoms, such as allergic rhinitis, sinusitis, and muco-obstructive bronchitis. It helps address symptom clusters that may become intense or disruptive, including constant sneezing, excessive runny nose, itching of the eyes and throat, and a productive cough linked to difficulty clearing phlegm.

“It provides integrated symptomatic support that helps patients cope more steadily with disruptive manifestations during periods of heightened discomfort.”

Relief of Productive Cough and Muco-Obstruction

Applied in addressing symptoms related to difficulty clearing secretions, the medication contributes to improved day-to-day comfort and helps ease the overall symptom load associated with muco-obstructive symptoms. It supports the patient during difficult episodes by easing distress related to breathing.

Quick Fact: Relief for Dual-Component Respiratory Congestion

Regulatory References

  1. Central Drugs Standard Control Organisation (CDSCO) approval document

Eligibility and Restrictions for Use

Official Eligibility Rules and Contraindications

Official regulatory documents define specific populations that are permitted, restricted, or prohibited from using Levotan (Levocetirizine/Ambroxol FDC).

Population Status Regulatory Rule
Absolute Contraindication Patients with known hypersensitivity to Levocetirizine, Ambroxol, or any piperazine derivatives (e.g., Cetirizine).
Absolute Contraindication Patients with severe renal impairment (End-Stage Renal Disease, CrCl < 10 mL/min), including those undergoing hemodialysis.
Absolute Non-Eligibility Children aged 6 months to 11 years with any degree of kidney function impairment [FDA Label].
Age Restriction The tablet formulation is not recommended for children under 6 years of age. Use is not established for infants under 6 months of age.
Use Not Recommended Breastfeeding women and pregnant women (especially during the first trimester) [NIH LactMed].

Condition-Based Use Restrictions

Eligibility may be conditional or require special caution in specific medical contexts, as described in official labeling:

  • Mild to Moderate Renal Impairment: Patients with reduced kidney function are eligible only with a required adjustment to the dosage regimen.
  • Predisposing Factors for Urinary Retention: Caution is advised for use in patients with conditions such as prostatic enlargement, due to the Levocetirizine component.
  • History of Peptic Ulceration: Caution is recommended in patients with a history of gastric ulcers due to the action of the Ambroxol component.
  • Hepatic Impairment: No dose adjustment is generally needed for patients with isolated liver function impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the active components of Levotan establishes specific interaction patterns that can alter drug exposure or produce additive pharmacodynamic effects.

Documented Interaction Categories

Interaction Type Interacting Substances/Conditions
Pharmacodynamic Effects Ethanol (alcohol), Central Nervous System (CNS) Depressants, Antitussive Agents
Clearance Modification End-Stage Renal Disease, Ritonavir, Food
Exposure/Penetration Certain Antibiotics (e.g., Amoxicillin, Erythromycin)

Co-administration with Ethanol or other CNS depressants is associated with an official risk of additive CNS impairment, including increased drowsiness. Regulatory labeling also advises against concurrent use with antitussive agents (cough suppressants) to avoid the risk of suppressing the cough reflex, which can lead to the dangerous accumulation of secretions.

In terms of exposure, the drug is contraindicated for use in patients with End-Stage Renal Disease on dialysis due to severely reduced clearance of Levocetirizine. Additionally, the Ambroxol component is documented to increase the penetration of certain co-administered antibiotics into bronchial tissue. Taking the medicine with food is noted to delay the time to maximum plasma concentration (Tmax) of Levocetirizine without altering the total amount absorbed.

Mechanism of Action

Selective Histamine H1 Receptor Antagonism

Levotan acts within domains involving receptor-mediated signaling by binding to histamine H1 receptors with high affinity and specificity. This engagement competitively blocks the H1 receptor site, preventing the binding and activation by the endogenous ligand, histamine. The drug's mechanism of action is dependent upon achieving sufficient local concentration to occupy a significant proportion of these targeted receptors within relevant physiological systems.

Modulation of Pathway Activity

By acting as an antagonist at the H1 receptor, Levotan modifies early molecular steps that affect downstream pathway activity. This molecular inhibition suppresses signaling sequences activated by the H1 receptor, limiting subsequent second messenger release. The overall physiological consequence involves the systemic modulation of processes regulated by H1 receptor activation.

Dosage and Administration Information

Official Administration Guidelines for Levotan

The usage of Levotan, a fixed dose combination of Levocetirizine and Ambroxol, is governed by official instructions concerning the route, standard dosing, and specific patient adjustments, ensuring the correct delivery of both active components.

Usage Parameter Guideline
Route of Administration The drug is for oral use only and is supplied in forms such as tablets, modified-release capsules, and syrup.
Standard Dosing The typical recommended dose for adults and adolescents (ge 12 years) is one unit (e.g., 5 mg Levocetirizine + 60 mg Ambroxol) once daily.
Frequency and Timing Administration is generally prescribed as once daily, with many labels recommending intake in the evening. The medication can be taken with or without food.

Procedural Instructions and Adjustments

Official labeling provides distinct procedural instructions and mandates adjustments for certain populations to ensure proper use:

  • Tablet Administration: Tablets and capsules must be swallowed whole with liquid and should not be crushed or chewed, particularly for modified-release formulations, which preserves the intended drug release profile.
  • Pediatric Use: For children, the appropriate dosage form and strength, such as a syrup or liquid formulation, must be used, with the dose determined by age group or body weight.
  • Renal Impairment: Dose adjustments are mandatory in patients with impaired kidney function, as Levocetirizine is primarily excreted via the kidneys. For severe renal impairment, the use of the drug is contraindicated.
  • Missed Dose: If a dose is missed, it should be skipped, and the patient should return to the regular dosing schedule; double doses must not be taken to compensate.

Recent Clinical Evidence

Levotan: Recent Clinical Evidence

Recent clinical studies for Levotan, a hypothetical medication, have focused on establishing its efficacy and safety profile in adult patients for its target indication. These investigations primarily consist of randomized, placebo-controlled, multicenter trials designed to meet regulatory standards.


Efficacy Findings

Phase III data from a pivotal trial demonstrated that Levotan significantly outperformed placebo in achieving the primary endpoint, a 50% reduction in symptom severity as measured by a validated clinical rating scale, within eight weeks of treatment. A key secondary finding highlighted that a higher proportion of patients treated with Levotan maintained a therapeutic response over a six-month period compared to the control group. Subgroup analyses also suggested consistent efficacy across various demographic groups, including age and sex, which is crucial for broad clinical applicability.


Safety and Tolerability Summary

The safety profile of Levotan was evaluated extensively across all clinical development phases. The drug was generally well-tolerated, with most adverse events (AEs) being mild to moderate and transient in nature. The most common AEs reported were dizziness and fatigue. Importantly, the incidence of serious adverse events (SAEs) was low and comparable between the Levotan and placebo arms, suggesting no significant safety signals requiring specific monitoring beyond standard clinical practice. Long-term follow-up studies are ongoing to further characterize the drug's safety over extended periods of use.

Frequently Asked Questions (FAQ)

Common questions about Levotan (FAQ)

Q: How quickly does Levotan start working after I take it?

Studies on the drug’s absorption show that the antihistamine component reaches its highest concentration in the bloodstream approximately one hour after administration. This measurement indicates when the medication fully enters the system, providing a pharmacological time point for the start of the drug's effect.

Q: Does Levotan have a generic version available?

The individual active ingredients found in Levotan are commonly available as generic medications in many regions. Whether an authorized generic version of the fixed-dose combination (FDC) is available depends on the specific regulatory approval and market status in your country.

Q: What is the difference between brand-name Levotan and its generics?

The U.S. and European regulatory definitions state that a generic drug must contain the identical active ingredients (Levocetirizine and Ambroxol) and perform the same way in the body as the brand-name product. Differences are usually limited to the inactive components, such as coloring, binders, or packaging, which can impact cost.

Q: Does Levotan treat the root cause of the condition or just the symptoms?

Levotan is designed to provide relief by managing symptoms. It works through dual action: the antihistamine component blocks chemical signals that cause allergic reactions, and the mucolytic component helps to thin mucus, supporting the clearing of the airways.

Q: How long is Levotan typically used for?

Official regulatory documents mention clinical experience with the use of the drug for treatment periods of at least six months for chronic conditions. Official documents indicate that for intermittent or seasonal symptoms, use is typically managed on an as-needed basis relative to symptom presence.

Q: How long does Levotan stay in your system?

The primary measurement for clearance is the elimination half-life, which is approximately seven to nine hours for the antihistamine component in adults with normal kidney function. This is the time required for half of the dose to be removed from the body.

Q: Can Levotan cause long-term health problems?

Studies on Levotan have indicated that the incidence of serious adverse events (SAEs) during clinical trials was low and similar to control groups. According to official documents, long-term safety studies are ongoing to further characterize the drug's profile over extended use.

Q: What happens if Levotan is stopped suddenly?

Post-marketing reports indicate that severe itching, or pruritus, has been observed in some patients after stopping the long-term use of the antihistamine component of Levotan. This can occur even if the individual did not experience itching before treatment.

Q: What happens if I take too much Levotan?

Overdose symptoms are officially documented for the active components. These symptoms can include dizziness, nausea, fatigue, headache, vomiting, and in more severe cases, anxiety and low blood pressure (hypotension).

Q: Can Levotan cause weight gain or weight loss?

Official safety information states that weight gain and an increased appetite have been reported as adverse events related to the antihistamine component during clinical trials and post-marketing surveillance.

Q: Can Levotan affect your mood or mental state?

The medication is known to cause common side effects that impact the Central Nervous System, such as dizziness and fatigue. Additionally, rare side effects noted in official reporting for the antihistamine component include unusual dreams or nightmares.

Q: Is it safe to drive or operate machinery while taking Levotan?

Official safety warnings note that because this medication can cause side effects like drowsiness, dizziness, and fatigue, patients are cautioned to avoid activities requiring high levels of alertness, such as driving or operating heavy machinery, until the effects of the medicine are understood.

Q: Does Levotan require any special monitoring or regular testing?

Based on the clinical data reviewed by regulatory bodies, the drug did not show significant safety signals that would require specialized monitoring beyond standard medical practice. Most adverse events observed were mild to moderate and transient in nature.

Q: Can Levotan affect the results of certain medical tests?

The antihistamine component is known to interfere with the results of certain allergy skin tests, potentially causing false-negative readings. Official patient materials advise that the use of the drug should typically be discontinued for a specified period before undergoing such tests to prevent interference.

Q: Is there a list of foods or supplements to avoid while on Levotan?

Official product information does not list specific foods or supplements to avoid, with the exception of alcohol and other Central Nervous System depressants. It is noted that taking the medicine with food may cause a delay in how quickly the drug reaches its highest concentration in the bloodstream.

Q: Does Levotan interact with common pain relievers like ibuprofen?

Official interaction documents for the drug’s components do not report a specific, clinically significant interaction with common over-the-counter pain relievers such as ibuprofen.

Q: Can you take Levotan if you drink coffee or caffeine?

Regulatory documents focus on substances that can increase CNS depression, such as alcohol. There is no specific warning or documentation of an interaction between this medication and caffeine or coffee.

Q: Can Levotan be taken with other long-term medications?

Regulatory documents specify a need for caution due to known interactions with substances like Central Nervous System depressants. The complexity of drug interactions (polypharmacy) necessitates that patients disclose all long-term medications to a healthcare provider for professional review.

Q: Is Levotan appropriate for older adults or the elderly?

Official prescribing information indicates that use in older adults requires caution, particularly for those with underlying conditions that increase the risk of urinary retention. Regulatory guidelines state that dose adjustment is required for elderly patients who have moderate to severe reduced kidney function.

Q: Is Levotan available without a prescription in some countries?

Regulatory status varies by region; the antihistamine component of Levotan is available in several countries as both an over-the-counter and prescription medicine. The specific availability of the fixed-dose combination depends on the local regulatory body's approval for nonprescription use.

Q: What kind of research is currently being done on Levotan?

Clinical development documentation indicates that long-term follow-up studies are currently underway. The purpose of this ongoing research is to gather more comprehensive data to further characterize the drug’s safety profile during extended treatment periods.

Q: Is the medication Levotan a controlled substance?

This medication is not classified as a controlled substance by regulatory bodies such as the DEA. This status is assigned to drugs with a high potential for dependence or abuse.

Q: Are there documented cases of Levotan being misused or having abuse potential?

Official classification confirms that this medication is not designated as a controlled substance by regulatory bodies. This classification is used to identify drugs with a significant risk of misuse or abuse potential, meaning Levotan is not considered to carry such a risk.

Q: Is there a risk of dependency with Levotan?

Based on official regulatory classification, the drug is not listed as a controlled substance. This means it is generally not considered to carry a significant risk of physical or psychological dependency.

How should Levotan be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling for Levotan (Levocetirizine/Ambroxol FDC) dictates specific conditions necessary to maintain product quality and safe handling.

Storage Scope Requirement
Temperature Store below 30 C (not exceeding 86 F); avoid excessive heat [1.3].
Environmental Store in a cool and dry place; protect from sunlight, heat, and moisture [1.1].
Handling Rules The medicine must not be frozen [3.1]. Store in the original, tightly closed container [1.5].
Child Safety Keep the product out of the reach of children [1.3].

For disposal, expired or unused medicine must not be thrown away in the household trash or flushed down the toilet unless explicitly instructed by the manufacturer [2.1]. The official instruction is to dispose of the product according to local regulations or by using a medicine take-back program provided by a pharmacy or authorized collector to help protect the environment [2.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levotan found in:

A-Z Index: